Self-rated global measure of the frequency, intensity, and burden of side effects

Stephen R. Wisniewski, A. John Rush, G. K. Balasubramani, Madhukar H. Trivedi, Andrew A. Nierenberg

Research output: Contribution to journalArticle

181 Citations (Scopus)

Abstract

No standard side-effect measure currently available can be easily used in clinical practice for patients receiving treatment for depression. The Frequency, Intensity, and Burden of Side Effects Rating (FIBSER) Scale was developed to document these three domains of side effects in patients treated in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) project. This article presents data on the reliability and validity of the FIBSER. The STAR*D prospectively enrolled 4,041 outpatients with nonpsychotic major depressive disorder (MDD) who were seeking medical care (as opposed to symptomatic volunteers recruited via advertisements). The patients were treated with citalopram. Clinical assessments, including the FIBSER, were completed at 2, 4, 6, 9, 12, and, if necessary, 14 weeks after enrollment. The FIBSER was shown to be reliable, with high correlations between observations taken a short time apart, and correlations decreasing as time between observations increased. There were also consistent relationships between items over time. The FIBSER has both face and construct validity. Thus, the FIBSER is a reliable and valid self-report measure of side effects in a population receiving treatment for depression. Although it does not measure the impact of specific side effects, it does measure three domains of impact: frequency, intensity, and burden of the side effects. Its brevity makes it a useful tool for routine clinical practice. These advantages are not available in other side-effect measures.

Original languageEnglish (US)
Pages (from-to)71-79
Number of pages9
JournalJournal of Psychiatric Practice
Volume12
Issue number2
DOIs
StatePublished - Mar 2006

Fingerprint

Depression
Reproducibility of Results
Citalopram
Major Depressive Disorder
Therapeutics
Self Report
Volunteers
Outpatients
Population

Keywords

  • Burden
  • Frequency
  • Intensity
  • Measurement tools
  • Rating scales
  • Sequenced Treatment Alternatives to Relieve Depression (STAR*D)
  • Side effects

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Self-rated global measure of the frequency, intensity, and burden of side effects. / Wisniewski, Stephen R.; Rush, A. John; Balasubramani, G. K.; Trivedi, Madhukar H.; Nierenberg, Andrew A.

In: Journal of Psychiatric Practice, Vol. 12, No. 2, 03.2006, p. 71-79.

Research output: Contribution to journalArticle

Wisniewski, Stephen R. ; Rush, A. John ; Balasubramani, G. K. ; Trivedi, Madhukar H. ; Nierenberg, Andrew A. / Self-rated global measure of the frequency, intensity, and burden of side effects. In: Journal of Psychiatric Practice. 2006 ; Vol. 12, No. 2. pp. 71-79.
@article{cfe37704bab74a929a43536743df880f,
title = "Self-rated global measure of the frequency, intensity, and burden of side effects",
abstract = "No standard side-effect measure currently available can be easily used in clinical practice for patients receiving treatment for depression. The Frequency, Intensity, and Burden of Side Effects Rating (FIBSER) Scale was developed to document these three domains of side effects in patients treated in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) project. This article presents data on the reliability and validity of the FIBSER. The STAR*D prospectively enrolled 4,041 outpatients with nonpsychotic major depressive disorder (MDD) who were seeking medical care (as opposed to symptomatic volunteers recruited via advertisements). The patients were treated with citalopram. Clinical assessments, including the FIBSER, were completed at 2, 4, 6, 9, 12, and, if necessary, 14 weeks after enrollment. The FIBSER was shown to be reliable, with high correlations between observations taken a short time apart, and correlations decreasing as time between observations increased. There were also consistent relationships between items over time. The FIBSER has both face and construct validity. Thus, the FIBSER is a reliable and valid self-report measure of side effects in a population receiving treatment for depression. Although it does not measure the impact of specific side effects, it does measure three domains of impact: frequency, intensity, and burden of the side effects. Its brevity makes it a useful tool for routine clinical practice. These advantages are not available in other side-effect measures.",
keywords = "Burden, Frequency, Intensity, Measurement tools, Rating scales, Sequenced Treatment Alternatives to Relieve Depression (STAR*D), Side effects",
author = "Wisniewski, {Stephen R.} and Rush, {A. John} and Balasubramani, {G. K.} and Trivedi, {Madhukar H.} and Nierenberg, {Andrew A.}",
year = "2006",
month = "3",
doi = "10.1097/00131746-200603000-00002",
language = "English (US)",
volume = "12",
pages = "71--79",
journal = "Journal of Psychiatric Practice",
issn = "1527-4160",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Self-rated global measure of the frequency, intensity, and burden of side effects

AU - Wisniewski, Stephen R.

AU - Rush, A. John

AU - Balasubramani, G. K.

AU - Trivedi, Madhukar H.

AU - Nierenberg, Andrew A.

PY - 2006/3

Y1 - 2006/3

N2 - No standard side-effect measure currently available can be easily used in clinical practice for patients receiving treatment for depression. The Frequency, Intensity, and Burden of Side Effects Rating (FIBSER) Scale was developed to document these three domains of side effects in patients treated in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) project. This article presents data on the reliability and validity of the FIBSER. The STAR*D prospectively enrolled 4,041 outpatients with nonpsychotic major depressive disorder (MDD) who were seeking medical care (as opposed to symptomatic volunteers recruited via advertisements). The patients were treated with citalopram. Clinical assessments, including the FIBSER, were completed at 2, 4, 6, 9, 12, and, if necessary, 14 weeks after enrollment. The FIBSER was shown to be reliable, with high correlations between observations taken a short time apart, and correlations decreasing as time between observations increased. There were also consistent relationships between items over time. The FIBSER has both face and construct validity. Thus, the FIBSER is a reliable and valid self-report measure of side effects in a population receiving treatment for depression. Although it does not measure the impact of specific side effects, it does measure three domains of impact: frequency, intensity, and burden of the side effects. Its brevity makes it a useful tool for routine clinical practice. These advantages are not available in other side-effect measures.

AB - No standard side-effect measure currently available can be easily used in clinical practice for patients receiving treatment for depression. The Frequency, Intensity, and Burden of Side Effects Rating (FIBSER) Scale was developed to document these three domains of side effects in patients treated in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) project. This article presents data on the reliability and validity of the FIBSER. The STAR*D prospectively enrolled 4,041 outpatients with nonpsychotic major depressive disorder (MDD) who were seeking medical care (as opposed to symptomatic volunteers recruited via advertisements). The patients were treated with citalopram. Clinical assessments, including the FIBSER, were completed at 2, 4, 6, 9, 12, and, if necessary, 14 weeks after enrollment. The FIBSER was shown to be reliable, with high correlations between observations taken a short time apart, and correlations decreasing as time between observations increased. There were also consistent relationships between items over time. The FIBSER has both face and construct validity. Thus, the FIBSER is a reliable and valid self-report measure of side effects in a population receiving treatment for depression. Although it does not measure the impact of specific side effects, it does measure three domains of impact: frequency, intensity, and burden of the side effects. Its brevity makes it a useful tool for routine clinical practice. These advantages are not available in other side-effect measures.

KW - Burden

KW - Frequency

KW - Intensity

KW - Measurement tools

KW - Rating scales

KW - Sequenced Treatment Alternatives to Relieve Depression (STARD)

KW - Side effects

UR - http://www.scopus.com/inward/record.url?scp=33745598890&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745598890&partnerID=8YFLogxK

U2 - 10.1097/00131746-200603000-00002

DO - 10.1097/00131746-200603000-00002

M3 - Article

C2 - 16728903

AN - SCOPUS:33745598890

VL - 12

SP - 71

EP - 79

JO - Journal of Psychiatric Practice

JF - Journal of Psychiatric Practice

SN - 1527-4160

IS - 2

ER -